Clinical Trials
I2B has recognized expertise in the design and management of clinical trials (phase I - IV) in inflammatory and autoimmune diseases. This comprises several medical fields including internal medecine, rheumatology, gastroenterology, nephrology, pulmonology, ophthalmology and neurology.
WP3
DFIL2
Dose-effect Relationship of Low-dose IL-2 in Type 1 Diabetes
IL-2 is an inducer of regulatory T cells (Treg), a population of lymphocytes that fail to control the autoimmune destruction of beta-cells in patients with Type 1 D...
IL-2 is an inducer of regulatory T cells (Treg), a population of lymphocytes that fail to control the autoimmune destruction of beta-cells in patients with Type 1 D...
WP3
DIABIL2
European phase-II
clinical trial evaluating efficacy of low dose rhIL-2 in patients with
recently-diagnosed type 1 diabetes
Clinical and preclinical studies, together with supportive mechanistic da...
Clinical and preclinical studies, together with supportive mechanistic da...
DHU:i2B
Phase IV Study CL3-12911-040
Long-term follow-up of patients from CL3-12911-018 study (5 year knee prosthesis in patients with knee osteoarthritis)
Sponsor: Pfizer
Sponsor: Pfizer
DHU:i2B
Rheumatoid Arthritis
A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis.
An exploratory clinical study to investigate mavrilimumab, an antibody being developed for the treatment of moderate to severe rheumato...
An exploratory clinical study to investigate mavrilimumab, an antibody being developed for the treatment of moderate to severe rheumato...
WP3
TRANSREG
TRANSREG is a multicentric, uncontrolled, open-label study, comparing biological and clinical responses to the administration of low dose of IL-2 across 11 selected pathologies (12 patients/pathology): rheumatoid arthritis, ankylosing spondyliti...
WP3
Impact Crohn
Impact of the Fecal Flora Transplantation on Crohn's DiseaseCrohn's disease is a chronic and relapsing inflammatory bowel disease. Many data show that the intestinal flora is involved in the disease and it has been show t...
WP3
MSIL2
Biological activity and safety of low dose IL2 in Relapsing Remitting Multiple Sclerosis
Interleukin‐2 (IL‐2) was initially discovered and used as a stimulator of effector T lymphocytes (Teffs), but is now viewed as a very promising...
Interleukin‐2 (IL‐2) was initially discovered and used as a stimulator of effector T lymphocytes (Teffs), but is now viewed as a very promising...
DHU:i2B
QUO VADIS
A prospective observational study to evaluate the relationship between disease state and change in quality of life in Ankylosing Spondylitis patients treated with Remicade (infliximab) or S...
DHU:i2B
SPACING
Effect of Spacing of Anti-TNF Drugs in Ankylosing Spondylitis With Low Disease Activity
Patients with spondyloarthritis, already treated by TNF blocker (adalimumab, etanercept or infliximab), and in stable low disease activity for at...
Patients with spondyloarthritis, already treated by TNF blocker (adalimumab, etanercept or infliximab), and in stable low disease activity for at...